Mary White Scharf
Dr. Mary E. White-Scharf is Senior
Vice President of Research at BioTransplant Incorporated, a company that is
developing products to address the current challenges in transplantation
medicine. She joined the company in 1991 as Director of Monoclonal
Antibodies and led the project to develop BTI-322®, an anti-CD2
monoclonal antibody, the humanized version of which is currently in clinical
trials for treatment of psoriasis. In
1995, she was promoted to Vice President of Research and assumed leadership of
the XenoMune program, a system being developed to enable transplantation of
porcine organs into humans. Prior
to joining BioTransplant, Dr. White-Scharf held the position of Research
Scientist at Repligen, where she led efforts to develop monoclonal antibodies
directed against the V3 loop of HIV-1.
To return to previous topic, click on your browser's 'Back' button.